<DOC>
<DOCNO>EP-0625166</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SULPHATED POLYSACCHARIDES, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
</INVENTION-TITLE>
<CLASSIFICATIONS>A61L3300	A61P702	C08B3710	A61K31726	A61L3300	A61K31737	A61K31715	C08B3700	C08B3700	A61K31715	A61L3308	A61K31727	A61K31737	A61P700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61L	A61P	C08B	A61K	A61L	A61K	A61K	C08B	C08B	A61K	A61L	A61K	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61L33	A61P7	C08B37	A61K31	A61L33	A61K31	A61K31	C08B37	C08B37	A61K31	A61L33	A61K31	A61K31	A61P7	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
RHONE POULENC RORER SA
</APPLICANT-NAME>
<APPLICANT-NAME>
RHONE-POULENC RORER S.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
UZAN ANDRE
</INVENTOR-NAME>
<INVENTOR-NAME>
UZAN, ANDRE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Mixture of sulphated oligosaccharides 
having the general structure of the constituent oligosaccharides 

of heparin, characterized in that it 
comprises at least 70 % of oligosaccharides having a 

molecular weight between 5,400 and 7,800 daltons, at 
least 5 % of oligosaccharides having a molecular weight 

greater than 6,900 daltons, and in that it has an anti-IIa 
activity greater than 60 IU/mg (method of Anderson 

L.O. et al., Thrombosis Research, 
15
 (1979), 531-541, 
with WHO LMWH1 as standard). 
Mixture according to claim 1, characterized 
in that it comprises at least 70 % of oligosaccharides 

having a molecular weight between 5,700 and 
7,500 daltons. 
Mixture according to claim 2, 
characterized in that it comprises at least 60 % of 

oligosaccharides having a molecular weight between 5,700 
and 6,900 daltons. 
Mixture according to one of claims 1 to 3, 
characterized in that it comprises at least 10 % of 

oligosaccharides having a molecular weight greater than 
6,900 daltons. 
Mixture according to one of claims 1 to 4, 
characterized in that it has an anti-IIa activity equal 

to or greater than 70 IU/mg. 
Mixture according to one of claims 1 to 5, 
characterized in that it is a fraction of heparin. 
Mixture according to one of claims 1 to 5, 
characterized in that it is a fraction of depolymerized 

heparin.  
 
Mixture according to claim 7, characterized 
in that it consists of oligosaccharides having a 

2-
O
-sulpho-4-enopyranosuronic acid at one of their ends. 
Mixture according to claim 8, characterized 
in that it is a heparin fraction which has been 

depolymerized by the action of a base on a heparin ester. 
Process for the preparation of a mixture 
according to one of claims 1 to 9, characterized in that 

a heparin or a depolymerized heparin is fractionated by 
gel filtration, this fractionation successively 

comprising steps consisting in (i) dissolving the 
starting heparin or depolymerized heparin in the eluent, 

(ii) passing the solution thus obtained through a column 
containing at least the solid support for the gel 

filtration which has been equilibrated beforehand with 
the same eluent, and (iii) recovering the fractions of 

desired molecular weight. 
Process according to claim 10, characterized 
in that a depolymerized heparin is used. 
Process according to claim 11, characterized 
in that a heparin is used which has been 

depolymerized by the action of a base on a heparin ester. 
Process according to claim 10, characterized 
in that, during the second step of the 

fractionation, the support is distributed in several 
columns arranged in series. 
Process according to claim 10, characterized 
in that the second step is performed by successively 

using at least 2 types of support, having different 
separation characteristics. 
Pharmaceutical composition having as 
active principle a mixture of oligosaccharides according 

to any one of claims 1 to 9. 
Pharmaceutical composition according to 
claim 15, which is intended fo
r the treatment and for the 
prevention of venous and arterial thrombosis. 
Pharmaceutical composition according to 
claim 15, which is intended for the prevention of 

arterial thrombotic accidents, in particular in the case  
 

of myocardial infarction. 
Pharmaceutical composition according to 
claim 15, which is intended for use in post-operative 

care, in the prevention of venous thrombosis in surgical 
patients. 
Use of a mixture of oligosaccharides 
according to any one of claims 1 to 9 in the prevention 

of thrombosis in the surgical equipment. 
</CLAIMS>
</TEXT>
</DOC>
